Clinical trial
Rituximab to Treat Severe Hemophilia A
NCT00331006 · Carelon Research, Other · Completed
Key facts
| NCT number | NCT00331006 |
|---|---|
| Title | Rituximab to Treat Severe Hemophilia A |
| Official title | Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study) |
| Acronym | RICH |
| Lead sponsor | Carelon Research, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 23 |
| Start date | Jun 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Jan 1, 2012 |
| First posted | May 29, 2006 |
| Last update posted | Jun 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: